Purified Cannabinoids Open New Opportunities in Pain Management

Date : 12/05/2017 @ 1:45PM
Source : NetworkNewsWire
Stock : Aphria Inc. (QB) (APHQF)
Quote : 11.57  0.0 (0.00%) @ 7:05AM

Purified Cannabinoids Open New Opportunities in Pain Management

NetworkNewsWire Editorial Coverage: As more Canadians than ever suffer chronic pain, the chase is on to find novel therapeutic approaches to effectively manage their conditions. In fact, BMC Public Health estimates that 20% of adults on a global level suffer from chronic pain while 10% are newly diagnosed every year. In Canada, chronic pain affects 1.5 million people. As national and worldwide numbers in pain diagnoses continue to rise, innovators in the cannabis industry are developing promising therapies to address this growing market.  InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB), Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED), Aphria, Inc. (OTCQB: APHQF) (TSX: APH) and Isodiol International, Inc. (OTCQB: ISOLF) (ISOL: CNX) each play a unique role in the increased acceptance and promise of medical marijuana and its purified derivatives for pain management and other medical needs.

The medical cannabis industry in Canada alone has gained impressive traction since its legalization in 2001, and industry statistics show increases from CAD$49 million in 2015 to projections of over $1.1 billion by the year 2020. Scientists, doctors, and pharmaceutical companies alike attribute this never-before seen rise in the market to consumer confidence in the therapeutic qualities of cannabis-derived products.

As consumer acceptance continues to propel demand to unprecedented levels, companies such as InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) are making waves in the advancement of cannabinoid compounds as a medical solution in pain management and other indications. The biopharmaceutical company focuses its efforts in the development of novel therapies surrounding the extensive pharmacology of cannabinoids (cannabis’ bioactive compounds) and innovative drug delivery systems.

Canadian marijuana companies are leading the way on a global scale by establishing high standards in the growing and cultivation of quality products. InMed is taking a very unique approach by focusing on a proprietary cannabinoid manufacturing process that sets it apart as a catalyst of improvement in the availability of pharmaceutical-grade cannabinoids.

The company’s proprietary biosynthesis process has the ability to combine the intrinsic safety and efficacy of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. Aside from significant cost savings, this process enables enhanced production, purification, and quality control compared to the typical grow-harvest-extract-purify methods employed by other companies. Notably, InMed’s biosynthesis system allows the manufacturing of all of the 90+ naturally occurring cannabinoids at a relatively low cost, regardless of how rare each compound may be in nature.

Using its exclusive process in a controlled laboratory setting, InMed can manufacture cannabinoid compounds that are identical to those found in nature without the difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis then laboriously extracting the individual cannabinoids for medical use. It also completely eliminates any need for fertilizers or pesticides.

Earlier this year, InMed Pharmaceutical filed a provisional U.S. patent for its pain management program (http://nnw.fm/6GHOq). The program, which includes the INM-405 therapy, along with other similar compositions of cannabinoid-based topical therapies for the treatment of pain, is an important step to not only protecting the company’s commercial and intellectual property, but also in establishing themselves as a major player in the pain management industry.

While there are numerous pharmaceutical products to treat both acute and chronic pain, the increase in the number of prescriptions for opioids has led to concerns of addiction, damaging side effects, and death. According to the U.S. Centers for Disease Control and Prevention, drug overdose deaths continue to increase in the United States, with the majority (more than 60%) involving an opioid. Since 1999, the number of overdose deaths involving opioids (including prescription opioids and heroin) quadrupled, as have the number of prescriptions for opioids, yet there has been no increase in the amount of pain reported in the general population. Thus, there is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed is researching the potential of non-THC (tetrahydrocannabinol, a psychoactive ingredient in cannabis) cannabinoids to treat pain using a proprietary topical formulation.

InMed’s advancements can be attributed to the company’s proprietary bioinformatics assessment tool, which is able to identify which cannabinoids can potentially target individual diseases (including pain).

As Canada’s medical marijuana industry continues to grow at a rapid rate, licensed producers of medical cannabis crops and pharmaceutical-grade cannabinoids are placing special emphasis on areas such as consistency and efficiency in order to keep up with market demands and provide easier product access, especially surrounding treatable conditions like pain management.

Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB), award-winning contributor to Canada’s legal medical cannabis industry, provides top-quality cannabis to patients through laboratory tested products, culture-minded cultivators, and a network of highly educated doctors in the cannabis industry. It is with these quality processes that they help to remove barriers of access.

Every patient’s symptoms and situation is completely unique, and so should be the care they receive. Aphria (OTCQB: APHQF) (TSX: APH), a producer of high-quality, pure and safe cannabis, combines superior patient care with products that are safe and consistent, with a commitment to exceeding baseline government and regulatory body standards for medical cannabis products. When it comes to medicine, adequate is simply not good enough. Aphria’s priorities lie within consistency, safety and efficacy.

Others, such as Canopy Growth (OTC: TWMJF) (TSX: WEED), is leading the world as a diversified cannabis company through its partnerships with leading names in the sector. The company’s core brands - Tweed, Spectrum Cannabis and Bedrocan Canada - don’t just sell quality cannabis and create meaningful customer relationships, they facilitate trusted conversations surrounding cannabis, simplify stakeholder outreaches, healthcare interactions, and patient education through color-identifying spectrum labeling, as well as a commitment to research, refinement, and licensing of medicinal cannabis products.

Companies such as Isodiol International (OTCQB: ISOLF) (ISOL: CNX) take their research and development a step further, focusing on the phytoceutical optimization of cannabinoids to maximize the bioactivity in the human body, allowing a more targeted treatment of specific health conditions. As an industry leader in the development and manufacturing of consumer products and raw ingredients derived from cannabis, Isodiol has pioneered many of the first hemp derivatives including micro-encapsulation for topical products, a 99% pure crystalline power, and nanotechnology for use in beverage and food applications.

Indeed, the overall support for medical cannabis appears to be on the rise, with an overwhelming amount of reports revealing high success in pain reduction as well as the reduction of other medication needs in the presence of medical marijuana and cannabinoid use. InMed Pharmaceuticals appears to be tackling these breakthroughs in conventional medication with its own scientifically derived advancements in the biosynthesis process. These advancements present a unique opportunity for those interested in investing in the rapid pace of the cannabinoid pharmaceutical and pain management industries.

For more information on InMed Pharmaceuticals, visit InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN)

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.




NetworkNewsWire (NNW) 
New York, New York 
212.418.1217 Office 

Aphria Inc. (USOTC:APHQF)
Historical Stock Chart

1 Year : From Dec 2017 to Dec 2018

Click Here for more Aphria Inc. Charts.

Aphria Inc. (USOTC:APHQF)
Intraday Stock Chart

Today : Thursday 13 December 2018

Click Here for more Aphria Inc. Charts.

Latest APHQF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.